All In Biotech

NDA 008085 · Strides Pharma Intl

Methotrexate Sodium

Methotrexate Sodium · Oral

NovelPriority reviewDiscontinued

Last checked: Nov 20, 2026Latest source record: May 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1953

Dec 7, 1953

Approved uses

3

Original approval plus efficacy supplements

Registered trials

2,087

570 Phase 3, 211 recruiting

FAERS reports

76,327

47,719 serious, 4,446 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 4, 2020 Supplement 71 · Efficacy LabelLetter
  • Oct 31, 1988 Supplement 28 · Efficacy
  • Dec 7, 1953 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • METHOTREXATE SODIUM · METHOTREXATE SODIUM EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Methotrexate" as an intervention, any sponsor and status, largest first.

All 2,087 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective19,726
  • drug hypersensitivity7,824
  • off label use6,466
  • rheumatoid arthritis5,720
  • drug intolerance5,635
  • nausea5,389
  • arthralgia5,078
  • pain5,067
  • condition aggravated4,721
  • fatigue4,529
  • joint swelling3,552
  • treatment failure3,321

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004767
2005506
2006181
2007249
2008267
2009263
2010161
2011385
2012682
2013772
2014513
20151,132
20164,126
201710,226
201812,491
20199,172
20206,834
20214,865
20226,005
20235,993
20245,136
20253,824
20261,777

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Methotrexate Sodium (Methotrexate Sodium/PF)

2024 spending

$901K

Beneficiaries

18,556

59,947 claims

Per beneficiary

$49

$1.50 per unit

View as table
YearSpending
2020$1,327,068
2021$1,357,555
2022$1,441,309
2023$843,319
2024$901,080

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,151 on PubMed

Sponsor: Strides Pharma Intl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.